On July 30, HENGRUI PHARMA fell 3.17% in regular trading, trading at HKD 56.4/share, with turnover of approximately HKD 98.92 million. The decline came despite a cluster of positive developments announced in recent days, as broad-based selling pressure across the pharmaceutical sector weighed on the stock.

On the news front, HENGRUI PHARMA recently secured NMPA approval for its independently developed insulin sudelidec injection — China's first domestically developed long-acting insulin analogue for adult Type 2 diabetes. Additionally, the company's HER3-targeted ADC, rekanluzetotab, had its marketing application accepted by the NMPA for EGFR-mutant non-small cell lung cancer. Capital Group also disclosed a 752,200-share stake increase at approximately HKD 56.76 per share, lifting its holding to 9.18%.

However, the pharmaceutical sector experienced significant across-the-board declines. Within the sector, CSPC Pharma fell 3.31%, SBP Group dropped 5.16%, Hansoh Pharma declined 2.39%, Asymchem slid 7.82%, while Sunshine Pharma rose 4.55%. The industry-wide selling pressure overwhelmed company-specific positive catalysts.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)